New potential inhibitors of mTOR: a computational investigation integrating molecular docking, virtual screening and...

Area of Science:

• Biochemistry and Molecular Biology
• Pharmacology and Drug Discovery
• Oncology

Background:

• The mammalian or mechanistic Target Of Rapamycin (mTOR) pathway is a critical regulator of cell growth and metabolism.
• Dysregulation of the mTOR pathway is implicated in the development of various cancers.
• Rapamycin and its analogs (rapalogs) are classical inhibitors targeting an allosteric site on the mTOR complex.

Purpose of the Study:

• To discover novel, non-ATP-competitive inhibitors of the mTOR enzymatic complex.
• To identify potential therapeutic agents for cancer treatment with improved safety profiles compared to ATP-competitive inhibitors.

Main Methods:

• Utilized ligand-based drug design strategies, including virtual screening.
• Employed computational determination of ADME/Tox properties for selected molecules.
• Applied molecular dynamics simulations to assess molecular interactions and stability.

Main Results:

• Identified five novel molecular entities with potential mTOR inhibitory activity.
• These compounds demonstrated favorable properties, comparable or superior to rapamycin.
• The identified inhibitors function via a non-ATP-competitive mechanism.

Conclusions:

• The study successfully identified promising novel mTOR inhibitors through computational drug design.
• These findings offer a foundation for developing new targeted cancer therapies.
• Further preclinical and clinical investigations are warranted to validate these potential drug candidates.